PMID- 31092459
OWN - NLM
STAT- MEDLINE
DCOM- 20190522
LR  - 20190522
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 39
IP  - 5
DP  - 2019 May
TI  - Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University 
      Hospital.
PG  - 2607-2614
LID - 10.21873/anticanres.13384 [doi]
AB  - BACKGROUND/AIM: To evaluate our initial experience with radium-223 chloride 
      (Ra-223). MATERIALS AND METHODS: A total of 26 castration-resistant prostate 
      cancer (CRPC) patients with bone metastases, treated with Ra-223 at our hospital 
      were evaluated. This study aimed to observe adverse events (AEs) and changes in 
      serum markers, and Bone Scan Index (BSI). Additionally, the relationship between 
      these values and OS was investigated. RESULTS: The observed AEs mainly included 
      fatigue and nausea. Alkaline phosphatase (ALP) and bone-type alkaline phosphatase 
      (BAP) levels decreased following the treatment; however, those of PSA and 1-CTP 
      tended to increase, regardless of Ra-223 administration. Overall survival (OS) 
      was significantly improved in cases with a baseline BSI value of <2 compared with 
      those with a baseline BSI value of >/=2. Moreover, the decrease in BSI after 
      administration of Ra-223 was an independent factor, significantly prolonging OS. 
      CONCLUSION: ALP and BAP levels and BSI values are suitable evaluation markers 
      during treatment with Ra-223. Also, baseline BSI values and the decrease in BSI 
      following treatment are independent factors predicting OS.
CI  - Copyright(c) 2019, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Nakashima, Kazufumi
AU  - Nakashima K
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Makino, Tomoyuki
AU  - Makino T
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Kadomoto, Suguru
AU  - Kadomoto S
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Iwamoto, Hiroaki
AU  - Iwamoto H
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Yaegashi, Hiroshi
AU  - Yaegashi H
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Iijima, Masashi
AU  - Iijima M
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Kawaguchi, Shohei
AU  - Kawaguchi S
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Nohara, Takahiro
AU  - Nohara T
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Shigehara, Kazuyoshi
AU  - Shigehara K
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Izumi, Kouji
AU  - Izumi K
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Kadono, Yoshifumi
AU  - Kadono Y
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Matsuo, Shinro
AU  - Matsuo S
AD  - Department of Nuclear Medicine Biotracer Medicine, Kanazawa University Graduate 
      School of Medical Science, Ishikawa, Japan.
FAU - Mizokami, Atsushi
AU  - Mizokami A
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan 
      mizokami@staff.kanazawa-u.ac.jp.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 8BR2SOL3L1 (Radium-223)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
RN  - W90AYD6R3Q (Radium)
SB  - IM
MH  - Aged
MH  - Alkaline Phosphatase/blood
MH  - Bone Neoplasms/blood/pathology/*radiotherapy/secondary
MH  - Bone and Bones/diagnostic imaging/radiation effects
MH  - Disease-Free Survival
MH  - Drug-Related Side Effects and Adverse Reactions/blood/classification/*pathology
MH  - Humans
MH  - Male
MH  - Prostate-Specific Antigen/blood
MH  - Prostatic Neoplasms, Castration-Resistant/blood/pathology/*radiotherapy
MH  - Radium/*administration & dosage
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Alkaline phosphatase
OT  - Bone Scan Index
OT  - castration-resistant prostate cancer
OT  - prostate cancer
OT  - radium-223 chloride
EDAT- 2019/05/17 06:00
MHDA- 2019/05/23 06:00
CRDT- 2019/05/17 06:00
PHST- 2019/03/11 00:00 [received]
PHST- 2019/04/18 00:00 [revised]
PHST- 2019/04/19 00:00 [accepted]
PHST- 2019/05/17 06:00 [entrez]
PHST- 2019/05/17 06:00 [pubmed]
PHST- 2019/05/23 06:00 [medline]
AID - 39/5/2607 [pii]
AID - 10.21873/anticanres.13384 [doi]
PST - ppublish
SO  - Anticancer Res. 2019 May;39(5):2607-2614. doi: 10.21873/anticanres.13384.